Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA; Department of Nephrology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, USA.
Kidney Int. 2020 Sep;98(3):541-543. doi: 10.1016/j.kint.2020.05.045.
Progressive focal segmental glomerulosclerosis, characterized by podocyte loss, is often refractory to treatment and leads to progressive proteinuric chronic kidney disease. Interleukin-9 (IL-9) is reported to play important roles in innate and adaptive immunity in extrarenal inflammatory diseases. By using an IL-9 knockout mouse model, Xiong et al. demonstrate IL-9 as a novel pro-podocyte survival cytokine in the adriamycin nephropathy model of focal segmental glomerulosclerosis. Sequential in vitro and in vivo data corroborate a direct protective role, rather than an immunologic role, for IL-9 on podocyte survival. This commentary highlights these novel data and discusses the necessary steps for developing IL-9 as a potential novel therapeutic for focal segmental glomerulosclerosis.
进行性局灶节段性肾小球硬化症，其特征是足细胞丧失，常对治疗有抗性，并导致进行性蛋白尿性慢性肾脏病。据报道，白细胞介素-9（IL-9）在肾脏外炎症性疾病的先天和适应性免疫中发挥重要作用。熊等人通过使用 IL-9 敲除小鼠模型，证明了 IL-9 是局灶节段性肾小球硬化症阿霉素肾病模型中新型促足细胞存活细胞因子。体外和体内的序贯数据证实了 IL-9 对足细胞存活的直接保护作用，而不是免疫作用。本评论强调了这些新数据，并讨论了将 IL-9 开发为局灶节段性肾小球硬化症潜在新型治疗方法的必要步骤。
